Renowned Former SmithKline & French Laboratories Executive Joins Kraig Advisory Board
LANSING, MI–November 22, 2010- Kraig Biocraft Laboratories, Inc. (KBLB) announced today that Raymond Kutsunai, the former general manager of SmithKline & French Laboratories, Japan, has joined the Company’s Board of Advisors.
Mr. Kutsunai was a central figure in SmithKline & French Laboratories operations and spectacular growth in Japan. Kutsunai is the second former major executive from SmithKline to join Kraig Biocraft Laboratories’ advisory board. Earlier this month SmithKline Beecham’s celebrated former CEO and Chairman Henry Wendt joined the Company’s Board of Advisors. SmithKline Beecham, which became Glaxo SmithKline, is one of the world’s largest and most successful corporations.
“Kraig Biocraft Laboratories is privileged to be able to attract this extraordinary level of talent,” said the Company’s founder and CEO Kim K. Thompson. “We are particularly excited about bringing Mr. Kutsunai onto the team. He rightfully deserves his stellar reputation in Japan for accomplishment and integrity. In addition to his extensive business experience and leadership Mr. Kutsunai also has extensive contacts in Japan which may prove to be invaluable as our Company grows. His proven record for orchestrating and managing explosive growth is exactly what we need as we move to commercialize our technologies.”
Kraig Biocraft Laboratories is a fully reporting biotechnology company, which recently achieved a series of scientific breakthroughs with implications for the global textile industry.
To learn more about Kraig Biocraft Laboratories and its recent commercial and scientific breakthroughs please visit www.KraigLabs.com. The website hosts several short videos describing the Company’s recent commercial and technological breakthroughs and outlines the commercial potential that has garnered attention of many scientific and trade journals.
Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “hopes,” “develops,” “researching,” “research,” “potential,” “implications,” “could” or other words or phrases of similar import. Similarly, statements in this release that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company’s financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.